Derick Reedy
Psychiatric/Mental Health · Nickelsville, VANPI 1427684562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,952 of the $23,202 with a category attached, or 64.4%. Johnson & Johnson accounts for 66.7% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $22,106, more than ten times the $17 reported in 2021. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $151.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- E.r. Squibb & Sons, L.L.C.$6K
- Teva Pharmaceuticals USA, Inc.$736
- AbbVie$329
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$320
- Vanda Pharmaceuticals Inc.$187
- plus $537 from 8 others
What the payments were for
- Speaking & faculty fees$14,95264%
- Travel & lodging$4,13018%
- Food & beverage$4,03917%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $15,469 |
| E.r. Squibb & Sons, L.L.C. | 28 | $5,625 |
| Teva Pharmaceuticals USA, Inc. | 22 | $736 |
| AbbVie | 28 | $329 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $320 |
| Vanda Pharmaceuticals Inc. | 5 | $187 |
| Alkermes, Inc. | 4 | $152 |
| Otsuka America Pharmaceutical, Inc. | 5 | $150 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,202 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 31 | $175,088 |
| SpravatoEsketamine Hcl | 87 | $142,286 |
| IngrezzaValbenazine Tosylate | 38 | $128,586 |
| AustedoDeutetrabenazine | 20 | $113,308 |
| UzedyRisperidone | 32 | $98,342 |
| Risperdal ConstaRisperidone Microspheres | 12 | $15,687 |
| RexultiBrexpiprazole | 16 | $11,746 |
| VraylarCariprazine Hcl | 13 | $10,050 |
| Olanzapine | 64 | $3,307 |
| Sertraline Hcl | 161 | $2,183 |
| Paliperidone ErPaliperidone | 11 | $2,077 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 20 | $2,026 |
| Buspirone Hcl | 73 | $1,554 |
| Duloxetine Hcl | 71 | $1,529 |
| Divalproex Sodium | 101 | $1,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $736 | $386,73883 claims |
| Johnson & JohnsonSpravato, Risperdal Consta | $15,469 | $157,97399 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $39 | $128,58638 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $150 | $11,74616 claims |
| AbbVieVraylar | $329 | $10,05013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Nickelsville
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Pamela RuppelRoanoke$21K
- Lisa Clement DefalcoEarlysville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.